Literature DB >> 28940502

Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center.

Shraddha Patkar1, Vikas Ostwal2, Anant Ramaswamy2, Reena Engineer3, Supriya Chopra3, Nitin Shetty4, Rohit Dusane5, Shailesh V Shrikhande1, Mahesh Goel1.   

Abstract

BACKGROUND AND OBJECTIVES: Gall bladder cancer (GBC) is a disease with high incidence in India. We analyzed the outcomes of patients with suspected GBC who underwent surgical exploration.
METHODS: Analysis of a prospectively maintained database of patients undergoing surgical exploration for clinic-radiologically suspected GBC from January 2010 to August 2015. Outcomes as well as factors influencing survival were analyzed.
RESULTS: Five hundred and ten patients underwent surgery for suspected GBC. Of these 400 had histologically proven malignancy. Eighty patients were deemed inoperable. Radical cholecystectomy was performed in 153 patients, revision surgery for incidental GBC in 160 and port site excision in seven patients. A total of 112 received peri-operative chemotherapy or chemoradiation. Majority were stage III (36%, n = 144) and stage II (31.8% n = 127). At a median follow up of 28.4 months, the median overall survival (OS) was not yet reached. Median disease free survival (DFS) was 33.4 months. Lymph node involvement, stage of the disease and resection status were the main factors influencing outcomes (P = 0.0001).
CONCLUSION: Surgery alone is curative only for early GBC (Stage I). Combination of surgery and peri-operative systemic therapy results in favorable outcomes even in stage II/III disease. Potentially, multimodality treatment may add meaningful survival for this disease with inherently aggressive tumor biology.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  gall bladder cancer; outcomes; surgical resection

Mesh:

Year:  2017        PMID: 28940502     DOI: 10.1002/jso.24837

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.

Authors:  Vikas Ostwal; Rohit Swami; Shraddha Patkar; Swaratika Majumdar; Mahesh Goel; Shaesta Mehta; Reena Engineer; Sarika Mandavkar; Suman Kumar; Anant Ramaswamy
Journal:  Med Oncol       Date:  2018-03-21       Impact factor: 3.064

Review 2.  Evaluation and management of incidental gallbladder cancer.

Authors:  Mohammad Y Zaidi; Ghassan K Abou-Alfa; Cecilia G Ethun; Shailesh V Shrikhande; Mahesh Goel; Bruno Nervi; John Primrose; Juan W Valle; Shishir K Maithel
Journal:  Chin Clin Oncol       Date:  2019-08-05

3.  Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India.

Authors:  Shaifali Goel; Abhishek Aggarwal; Assif Iqbal; Vineet Talwar; Swarupa Mitra; Shivendra Singh
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

4.  Determinants of curative resection in incidental gallbladder carcinoma with special reference to timing of referral.

Authors:  Kulbhushan Haldeniya; Ashish Singh; Neha Bhatt; Prabhakar Mishra; Rajneesh Kumar Singh; Rajan Saxena
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-11-30

5.  Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas-A Relatively Rare Component of Biliary Tract Cancers in India.

Authors:  Prabhat G Bhargava; Amit Kumar; Vijai Simha; Minit Shah; Shraddha Patkar; Mahesh Goel; Vikas Ostwal; Anant Ramaswamy
Journal:  South Asian J Cancer       Date:  2021-06-12

6.  A Novel Nomogram Predicting Distant Metastasis in T1 and T2 Gallbladder Cancer: A SEER-based Study.

Authors:  Yu-Long Cai; Yi-Xin Lin; Li-Sheng Jiang; Hui Ye; Fu-Yu Li; Nan-Sheng Cheng
Journal:  Int J Med Sci       Date:  2020-07-02       Impact factor: 3.642

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.